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Abstract
Objectives: The association between the presence and alterations of the components of the ghrelin system and the
development and progression of neuroendocrine tumors (NETs) is still controversial and remains unclear.
Methods: Here, we systematically evaluated the expression levels (by quantitative-PCR) of key ghrelin system
components of in gastroenteropancreatic (GEP)-NETs, as compared to non-tumor adjacent (NTA; n= 42) and normal
tissues (NT; n= 14). Then, we analyzed their putative associations with clinical-histological characteristics.
Results: The results indicate that ghrelin and its receptor GHSR1a are present in a high proportion of normal tissues,
while the enzyme ghrelin-O-acyltransferase (GOAT) and the splicing variants In1-ghrelin and GHSR1b were present in a
lower proportion of normal tissues. In contrast, all ghrelin system components were present in a high proportion of
tumor and NTA tissues. GOAT was significantly overexpressed (by quantitative-PCR (qPCR)) in tumor samples
compared to NTA, while a trend was found for ghrelin, In1-ghrelin and GHSR1a. In addition, expression of these
components displayed significant correlations with key clinical parameters. The marked overexpression of GOAT in
tumor samples compared to NTA regions was confirmed by IHC, revealing that this enzyme is particularly
overexpressed in gastrointestinal NETs, where it is directly correlated with tumor diameter.
Conclusions: These results provide novel information on the presence and potential pathophysiological implications
of the ghrelin system components in GEP-NETs, wherein GOAT might represent a novel diagnostic biomarker.
Introduction
Neuroendocrine tumors (NETs) comprise a heterogeneous
family of malignancies with complex clinical behavior and
increasing incidence1–3. Primary tumor is identified only in
70% of patients4, while distant metastases are frequently
found at diagnosis (27–73%), influencing the overall survi-
val5–7. Despite that histological differentiation and Ki67 index
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are some prognosis factors4, well-differentiated low-grade
tumors may behave aggressively8. Unfortunately, surgery is
often not applicable since most tumors are diagnosed at
advanced stage. For these reasons, the development of
novel diagnostic markers has gained scientific and clinical
interest9,10.
The ghrelin system is involved in the regulation of
multiple (patho)-physiological functions, including hor-
monal secretion, β-cell survival or appetite and gastric
motility11–14. Ghrelin must undergo a unique modifica-
tion, consisting of the acylation of the third serine residue,
which is catalyzed by the ghrelin-O-acyltransferase
(GOAT) enzyme14,15. Acylated ghrelin (AG) represents
the peptide binding and activating its canonical ghrelin
receptor, GHSR1a. Interestingly, several ghrelin system
variants, resulting from post-transcriptional modifications
or alternative splicing, have been identified, including the
In1-ghrelin11,16 and a truncated receptor GHSR1b, with
unknown ligand and function11,16,17.
Alterations in the expression of specific components of
this system have been associated with the development/
progression of various neoplasms16,18–21, including NETs,
but the clinical-molecular correlations have not been
elucidated22,23. Accordingly, in this study we aimed to: (1)
analyze systematically the expression of different com-
ponents of ghrelin system in gastroenteropancreatic-
(GEP-)NETs compared to non-tumor adjacent (NTA)
tissue and, most importantly, to normal control tissues by
quantitative real-time PCR (qPCR); (2) correlate the
expression of these components with clinical/histological
characteristics; and (3) perform in vitro experiments to
elucidate the potential pathophysiological role of GOAT
enzyme as a key component particularly altered in our




This study was approved by the Ethics Committee of the
Reina Sofia University Hospital (Cordoba, Spain), was
performed according to the Declaration of Helsinki, and
patients were treated following national and international
clinical practice guidelines. A written informed consent
was required before inclusion. Data from 42 patients with
GEP-NETs were collected (demographic and clinical
characteristics of the cohort are summarized in Table 1).
Additionally, 14 normal control tissues from healthy
donors were also included. Patients with hereditary
endocrine syndrome were excluded. Clinical records were
used to collect full medical history. GEP-NETs were
classified according to histopathology features as well-
differentiated NETs (G1), moderately differentiated (G2),
and poorly differentiated NETs (G3)24. Formalin-fixed
paraffin-embedded (FFPE) samples were also collected (42
tumor samples, 42 NTA and 14 normal tissues).
RNA isolation and reverse-transcription
Total RNA from FFPE samples (n= 98) was isolated
using the RNeasy-FFPE Kit (Qiagen, Limburg, Nether-
lands) according to the manufacturer’s instructions.
Quantification of the recovered RNA was assessed using
NanoDrop2000 spectrophotometer (Thermo Scientific,
Wilmington, NC). Total RNA was retrotranscribed to
cDNA with the First-Strand Synthesis kit using random
hexamer primers (Thermo Scientific) as previously
reported25–28
Quantitative real-time PCR (qPCR)
cDNAs were amplified with the Brilliant III SYBR-
Green Master Mix (Thermo Scientific) using the Strata-
gene Mx3000p system and specific primers for each
transcript of interest. Specifically, expression levels
(absolute mRNA copy number/50 ng of sample) of ghre-
lin, In1-ghrelin, GOAT enzyme, GHSR1a and GHSR1b,
were measured using previously validated primers21,29,30.
RNA expression was adjusted by 18S gene expression28,31.
Immunohistochemistry (IHC) analysis
IHC analysis of GOAT was implemented in all 42 FFPE
samples (tumor and NTA regions) using standard pro-
cedures32. Optimum antibody concentration (1:300) using
a commercially available antibody against human GOAT
(AA257-287, Acris-antibodies, Herford, Germany) was
selected by performing a series of antibody dilution tests
in normal pancreas33. Two independent pathologists
performed the IHC analysis following a blinded protocol.
Table 1 General characteristics of the patient population




Age at diagnosis 55.66 ± 17 years




No habit 35.0% (7)
Family history of neoplasms 52.9% (9)
Incidental tumor 37.9% (11)
Functionality 43.3% (13)
Mortality rate 18.9% (7)
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In the analysis, 0, 1+ , 2+ , 3+ stand for absent, low,
moderate, and high staining intensities of GOAT enzyme
in the tumor compared to the NTA region.
Cell culture
In vitro experiments were performed using human NET
cell lines BON-134 and QGP-135. BON-1 cells were cul-
tured in DMEMF12 (Life Technologies, Barcelona, Spain)
supplemented with 10% fetal bovine serum (FBS; Sigma-
Aldrich, Madrid, Spain), 1% glutamine (Sigma-Aldrich)
and 0.2% antibiotic (Gentamicin/Amphotericin-B; Life
Technologies). QGP-1 cells were cultured in RPMI-1640
(Lonza, Basel, Switzerland), supplemented with 10% FBS,
1% glutamine, and 0.2% antibiotic. Both cells lines were
cultured at 37 °C in a 5% CO2 incubator and monthly
checked for mycoplasma contamination by PCR36.
Cell proliferation assay in response to GOAT inhibitor
The only commercially available GOAT inhibitor
(GOATi; GO-CoA-Tat; Ref: 032–37) was purchased from
Phoenix Pharmaceuticals (Burlingame, CA). The final
concentration (10-5M) was selected based on
dose–response experiments performed in prostate cell-
lines and on previous reports37. Cell proliferation was
determined by using Alamar-blue assay (basal, 24, 48, and
72 h) as previously reported21,22,32. Cells were seeded per
quadruplicate and assays were repeated four times.
Paclitaxel (PAX; Sigma-Aldrich) was used as control for
the inhibition of proliferation27,30.
Migration capacity assay
The ability of BON-1 cells to migrate after 24 h of
treatment was evaluated by wound-healing techni-
que22,38–40. Briefly, stable cells were plated at sub-
confluence in 6-well plates. The wound was made on
confluent cells using a 100 μl sterile pipette tip. Wells
were rinsed in PBS and treated for 24 h in FBS-free
medium. Wound-healing was calculated as the area of a
rectangle centered in the picture 24 h after the wound vs.
the area of the rectangle just after doing the wound. Three
experiments were performed in independent days, in
which three random pictures per well along the wound
were acquired and, the mean area of these pictures was
used for analysis. Images were analyzed using the ImageJ
software41.
Statistical analysis
Paired t-test analysis was used to compare the expres-
sion levels between GEP-NETs samples and NTA tissue.
Non-paired t-test analysis was used to compare the
expression levels between normal tissue and GEP-NETs
samples or NTA tissue. U-Mann–Whitney tests were
used to evaluate clinical-molecular relations within GEP-
NETs samples. Chi-squared test was used to compare
categorical data. All statistical analyses were performed
using SPSS and GraphPad Prism. Data are expressed as
mean ± SEM. p-values < 0.05 were considered statistically
significant. In functional experiments, results were
expressed as percentage vs. control (vehicle-treated cells).
Cell proliferation rate compared to control was assessed
by multiple comparison test (two-way ANOVA followed
by Newman-Keuls post-hoc test).
Results
Forty-two patients with GEP-NETs were included.
Demographic/clinical features are summarized in Table 1.
Specifically, 15 patients presented PNETs and 27 patients
presented gastrointestinal (GI)-NETs [52.3% males (22/
42); mean age 55.6 ± 17 years]. Tumor characteristics are
summarized in Table 2. In our cohort, 43.3% (13/30) were
functioning tumors; 63.2% (24/38) had peritumoral inva-
sion [34.3% (12/35) vascular and 35.3% (12/34) neural
invasion], 52.4% (22/42) had metastasis at diagnosis
[multiple localization in 36.3% (8/22)], 63.2% (24/38)
were invasive tumors and the mortality rate reached
18.9% (7/37). Relapsed disease was observed in 36% of
patients (13/36). Finally, almost 70% of samples (29/42)
were considered as low/intermediate tumors [38.1%
(16/42) grade 1 and 31% (13/42) grade 2]. PNETs were
statistically larger in size compared to those GI-NETs (4.0
± 0.47 vs. 2.36 ± 0.34 cm, respectively; p < 0.01).
Histopathological characterization of GEP-NETs and NTA
tissue
Primary tumor samples were delimited from the NTA
tissues after the evaluation of two experienced patholo-
gists using histology and immunohistochemistry, as pre-
viously reported32.
Expression of components of the ghrelin system in control
and GEP-NETs samples
Ghrelin system components were present at variable
proportions in normal GEP samples, as determined by
qPCR. Ghrelin and its native receptor GHSR1a were
expressed in more than 80% of healthy controls (34/42
and 39/42, respectively), while their splicing variants In1-
ghrelin and GHSR1b were expressed in about 40% of the
samples (17/42 and 19/42, respectively). In contrast,
expression of GOAT enzyme was only detected in less
than 20% (7/42) of normal samples (Supp. Fig. 1). Ghrelin
and GHSR1a were also present in a high proportion (more
than 60%) of the NTA and tumor samples (32/42 and 29/
42, respectively); while GOAT enzyme and the splicing
variants In1-ghrelin and GHSR1b were present in more
than 40% of the samples (25/42, 21/42 and 17/42,
respectively; Supp. Fig. 1). Of note, ghrelin expression
levels were decreased in NTA and tumor tissue compared
with normal samples, with a slightly but not significantly
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increased expression in tumor compared with NTA tissue
(Fig. 1). A similar observation was found for GHSR1a
expression, while GOAT enzyme was clearly over-
expressed in tumor tissues compared with NTA regions
and normal tissues, wherein it was virtually absent (Fig. 1).
Finally, In1-ghrelin was more expressed in tumor tissues
than in control samples but these differences were not
statistically significant, while no significant changes were
found in the case of the splicing variant GHSR1b (Fig. 1).
In terms of tumor grade, no significant differences in
the expression of any of the ghrelin system components
analyzed were found between differentiated (G1/G2) and
non-differentiated (G3) GEP-NET (Supp. Fig. 2). How-
ever, we found that the expression of GOAT enzyme and
GHSR1a in GI-NETs was markedly higher than in PNETs,
while the expression of ghrelin was lower in GI-NETs
compared to PNETs (Supp. Fig. 3). Additionally, ghrelin
expression levels correlated with those of In1-ghrelin
(R2= 0.532; p < 0.01) and GOAT (R2= 0.422; p < 0.05) in
tumor samples, while the expression of GHSR1a was
correlated with GHSR1b (R2= 0.444; p < 0.05).
Immunohistochemistry analysis of the presence of GOAT
enzyme
Based on the marked overexpression of GOAT enzyme,
as well as on previous reports16,18, we also sought to
analyze its presence at the protein level. IHC analysis of
tumor tissue revealed that GOAT enzyme was present in
the vast majority of tumor cells compared with NTA
tissue (Fig. 2a), with different grades of staining. Indeed, in
our cohort, 86% of the tumor samples (36/42) evaluated
were positive for the presence of GOAT enzyme by IHC
(Fig. 2b), wherein 40% of the tumor cases (17/42) pre-
sented a strong staining (2+ or 3+ ) for GOAT com-
pared to NTA tissue (Fig. 2c, d). Of note, mRNA
expression levels in tumors samples correlated with
GOAT expression by IHC (Fig. 2e). Additionally, strong
staining (2+ or 3+ ) for GOAT was correlated to
increased age at diagnosis (62.5 ± 4 years) compared to
those tumors with absent or lower staining (0 or 1+ ; 51
± 2 years; p > 0.05).
Correlations between the expression levels of ghrelin
system components and clinical-histological characteristics
in GEP-NETs
Epidemiological data revealed that patients with tobacco
exposure exhibited higher expression of ghrelin and In1-
ghrelin (Fig. 3a). Moreover, patients with family history of
tumor disease had a lower expression of ghrelin (Fig. 3b).
Conversely, sex, personal history, previous neoplasm
history, clinical symptoms, or other histological para-
meters (vascular/peritumoral invasion, lymph node
metastasis) were not associated with the expression of any
of the components of the ghrelin system.









Small bowel 31.0% (13)
Colon and rectum 26.2% (11)
Maximal tumor diameter 2.98 ± 1.86 cm
Pancreas NETs 4.0±0.47 cm





> 30% 16.7% (1)





Multiple tumors 8.0% (2)
Peritumoral tissue invasion 63.2% (24)
Vascular invasion 34.3% (12)




Lymphatic nodules 54.5% (12)
Multiple 36.3% (8)





Post-surgical treatment 43.2% (16)
Relapsed disease 36.1% (13)
Disease free 55.9% (19)
New surgery requirements 18.2% (6)
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Expression of some ghrelin system components was also
associated to tumor characteristics, invasion capacity and
prognosis in GEP-NETs. Specifically, functioning tumors
presented higher levels of GHSR1a (Fig. 3c), while lower
expression levels of this receptor were associated to the
presence of affected surgical borders and mortality
(Fig. 3c). Tumors with necrosis had lower GOAT mRNA
levels and those with liver metastasis had decreased
expression levels of In1-ghrelin (Fig. 3d). Interestingly,
functionality was also associated with increased expres-
sion of GHSR1b (Fig. 3e). Finally, tumor diameter was
directly correlated to GOAT expression (R= 0.33; p <
0.05). Remarkably, no further associations were
found between expression levels of ghrelin system com-
ponents and clinical/histological characteristics when
considering separately PNETs and GI-NETs (data not
shown).
In vitro analysis of the role of GOAT in PNETs cell lines
We decided to further investigate the pathophysiologi-
cal role of GOAT enzyme using the only available GOATi
in PNETs cell lines. However, GOATi did not affect cell
proliferation in BON-1 and QGP-1 cells (Fig. 4a) or the
migration capacity of BON-1 cells (Fig. 4b).
Discussion
This study aimed at evaluating systematically the
expression of various components of the ghrelin system in
an ample series of clinically well-characterized GEP-
NETs, and to compare these expression levels with those
in the corresponding adjacent non-tumor tissues and in
normal control tissues. Previous studies have reported
certain components of the ghrelin system in GEP-
NETs22,42–44; however, to our knowledge, this is the first
study that comprehensively characterizes these compo-
nents in tumor samples compared to their corresponding
adjacent non-tumor regions, as well as with normal tissue
samples. Moreover, we analyzed the demographic,
epidemiological, and clinical characteristics as well as the
disease progression and prognosis after 2–10 years of the
patients with GEP-NETs. Overall, our results revealed
that most of the components of the ghrelin system exhibit
a distinctive expression in tumor and peritumoral tissues
compared to normal tissue samples. Indeed, specific
components of the ghrelin system, and especially GOAT,
displayed remarkable alterations and clinical-histological
correlations in tumor tissues, suggesting their potential
value as novel biomarkers in GEP-NETs.
Also in our cohort, GEP-NETs exhibited a substantial
molecular heterogeneity and variability22,32,45. Our results
are consistent with previous reports showing that differ-
ent components of the ghrelin system are present in
tumor and non-adjacent tissues, and that, some of these
components can be overexpressed in tumor samples
compared to the surrounding tissue22,42–44. Differences
among these studies may be related to the differences
among patient cohorts.
Ghrelin system regulates key bodily functions, such as
hormonal secretion and cell proliferation, in both normal
and tumor cells11–13,46,47. In this context, our and other
studies support the notion that the dysregulation of
ghrelin system components observed in NETs could be
pathologically relevant and may participate in tumor
progression. The diverse localization and morphology of
ghrelin-producing cells in the GI tract, and their impli-
cations on metabolic/endocrine functions, might suggest
a role of this component in the regulation of GEP-NETs
pathophysiology12,13,42, and could also explain the ample
molecular heterogeneity found herein in the expression of
ghrelin in different normal control tissues. Moreover, it
could also be related to the overall overexpression of
ghrelin in normal tissues compared to tumor samples.
Although expression of canonical ghrelin has been
described in various tumor types, its potential role in
cancer is still controversial48,49. Ghrelin has been descri-




















































































































































































































Fig. 1 Expression of ghrelin system components in normal GEP, adjacent non-tumor tissue and GEP-NETs. The absolute mRNA expression of the
different components of the ghrelin system was determined by qPCR in normal GEP controls, adjacent non-tumor tissue and GEP-NETs samples (values
are adjusted by 18S expression). Data represent the mean ± SEM. Asterisks (*p < 0.05; **p < 0.01; ***p < 0.001) indicate significant changes by paired
analysis between adjacent non-tumor and GEP-NETs and non-paired analysis between normal tissue and adjacent non-tumor or tumor tissues
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Fig. 2 Immunohistochemical analysis of GOAT enzyme in adjacent non-tumor tissue and GEP-NETs. The presence of GOAT by
immunohistochemistry using a specific antibody was determined in a subset of samples, which included tumor and non-tumor regions from patients
diagnosed with GEP-NETs. a Representative images of the IHC analysis of GOAT enzyme in a GEP-NET sample compared with the non-tumor adjacent
tissue. b Absolute number of cases according to the intensity of GOAT IHC staining (0, 1+ , 2+ , 3+ ). c The graph indicates the percentage of tumor
samples according to the intensity of GOAT expression by IHC, 0 and 1+ have been grouped as low expression while 2+ and 3+ have been grouped as
high intensity by IHC. d Representative images of different GOAT staining in GEP-NETs. In the analysis, 0, 1+ , 2+ , 3+ stand for absent, low, moderate,
and high intensities of the tumor region staining compared to the adjacent region with non-tumor tissue (3D1, 3D2, 3D3, 3D4, respectively).
This analysis revealed that GOAT was present in the vast majority of tumor cells compared with non-tumor adjacent tissue, with different grades of
staining. e Correlation between the absolute mRNA expression of GOAT determined by qPCR in GEP-NETs samples (values are adjusted by 18S
expression) and the intensity of GOAT staining
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qPCR22,25,42,43, in our cohort ghrelin was expressed in
NET samples, albeit in substantially lower amounts than
in normal tissues. In addition, in our cohort ghrelin
expression levels were higher in PNETs than in GI-NETs,
which is consistent with previous evidence43 but differed
from other reports44. At variance with previous studies
that did not find any clinical correlation between ghrelin
expression and clinical features22,42, we observed here that
ghrelin expression was higher in patients without tumor
family history. Similarly, the in vitro effects of ghrelin on
cell proliferation are also controversial48,50–56 and some
studies have reported an association between ghrelin and
poor survival in renal cell carcinoma patients57,58. Alto-
gether, these data reinforce the notion that NETs are
highly heterogeneous tumors, wherein the particular
ghrelin expression profile and its clinical implications may
depend on the type of tumor and the particular cohort of
patients analyzed.
Expression of the canonical ghrelin receptor GHSR1a
has been described in tumors including NETs22,25,48.
Here, GHSR1a expression was highly variable in normal
control samples, but tended to be overexpressed in tumor
samples compared to adjacent non-tumor tissue, which is
consistent with our previous study in a different cohort22.
The relation between GHSR1a, functionality and mor-
tality invites to explore further the potential relationship
of this receptor with tumorigenesis, and its putative value
as a molecular prognostic marker in NETs.
The pathophysiological implications of the ghrelin sys-
tem have been recently expanded with the discovery of
new molecular components11,16,17,29, which have been
found to be overexpressed in several tumors16,22,27 and
associated to relevant clinical parameters22. Herein we
found comparable tendencies in the expression of these
variants; however, these differences did not reach statis-











































































































































































































































































































































Fig. 3 Correlations between epidemiological, clinical, histological, and molecular parameters in GEP-NETs. The correlations between
epidemiological, clinical, histological, and molecular parameters within GEP-NET samples were assessed by U-Mann–Whitney tests. Asterisks indicate
significant associations (*p < 0.05; **p < 0.01; ***p < 0.001)
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>40% of tumor samples presented detectable levels of In1-
ghrelin and GHSR1b, while in the previous study, >80% of
the tumor samples exhibited detectable levels22. These
differences could likely reduce the statistical power of the
comparisons and correlations, and, again, would illustrate
the elevated heterogeneity of NETs.
The most novel and relevant finding of this study is the
marked overexpression of GOAT in NET samples.
Whereas the expression of this enzyme was almost absent
in control tissues, it was present in adjacent non-tumor
tissue and notably overexpressed in tumor tissues. These,
together with previous results showing a similar,
remarkable overexpression of GOAT in breast and
pituitary tumors11,21 provide suggestive evidence for a
striking dysregulation of this enzyme in endocrine-related
tumors. The expression levels GOAT does not always
correlate with those of ghrelin, whereas they do parallel
more consistently the expression levels of In1-ghrelin,
suggesting the existence of additional targets for GOAT
enzyme11. In NETs, GOAT levels have been correlated
with those of In1-ghrelin, and associated with worse
outcome22, these findings were not reproducible in our
cohort, which may be explained by the tumor hetero-
geneity and the limited number of tumor samples. Despite
this, in the present study, GOAT expression is associated
to larger tumors, especially in GI-NETs, reinforcing the
notion of a possible association between the dysregulation
of this enzyme and the pathophysiology of NETs. This is
the first study that demonstrates an intense over-
expression of GOAT enzyme by IHC in GEP-NETs tis-
sues compared to non-tumor adjacent tissues; however,
its functional implications should be precisely defined.
Here, a GOAT inhibitor administered on two NET cell
lines, BON-1 and QGP-1, did not show relevant changes
in cell proliferation or migration in vitro. Thus, future
studies should explore this further, using novel inhibitors
or other inhibiting/silencing approaches.
Notwithstanding this, our current and previous22 stu-
dies provide compelling evidence that certain components
of the ghrelin system, and specially GOAT enzyme, are
clearly overexpressed in NETs, suggesting their potential
value as diagnostic and/or prognostic biomarkers for this
pathology. In support of the present finding in NETs,
GOAT has been also recently reported as non-invasive
plasma biomarker in prostate cancer18. Additionally, the
association between GHSR1a and GHSR1b with
the functionally of these tumors and the mortality of these
patients further supports this notion and emphasizes the
importance of exploring the modulation of this receptor


































































































Fig. 4 In vitro analysis of the consequences of GOAT inhibitor (GOATi) treatment in NET cell lines. a Cell proliferation rate in BON-1 and QGP-1 cell
lines after 24, 48, and 72 h of GOATi treatment determined by Alamar-blue assay. Paclitaxel (PAX) was used as inhibitory control in proliferation assays.
b Cell migration rate in BON-1 after 24 h of treatment with GOAT inhibitor by wound-healing assay. Cell proliferation rate compared to control was
assessed by multiple comparison tests while migration was assessed by U-Mann–Whitney test. Values represent the mean ± SEM of at least three
individual experiments. Asterisks indicate significant differences (*p < 0.05; ***p < 0.001) compared with control (set at a 100%). Legend: ns means non-
significant
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difficult to predict the specific clinical impact of these
findings, taken together, all these results invite to analyze
in more detail the putative utility of GOAT over-
expression as a diagnostic biomarker in NETs.
In summary, we present the first systematic character-
ization of the components of the ghrelin system, including
splicing variants, in GEP-NETs tissues in comparison with
their adjacent non-tumor regions, and also with normal
tissue samples. Our results demonstrate that key com-
ponents of this system are markedly dysregulated in GEP-
NETs and associated to key clinical parameters, suggest-
ing the interest of further studying these molecular tar-
gets, especially GOAT, as putative diagnosis and/or
prognostic markers in GEP-NETs.
Study highlights
What is current knowledge
– Some components of ghrelin system could be altered
in neuroendocrine tumors
What Is New Here
– Key components of ghrelin system are markedly
dysregulated in GEP-NETs and associated to key
clinical parameters.
– Changes in the expression of ghrelin system compo-
nents are associated with the development and/or
progression of GEP-NETs.
– These molecular targets, especially GOAT, may
represent putative diagnosis and/or prognostic mar-
kers in GEP-NETs.
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